Wednesday, December 7, 2022
8:00 pm ET, 7:00 pm CT, 5:00 pm PT
James W. Ochi, MD, DABMA
Wednesday, December 7, 2022
8:00 pm ET, 7:00 pm CT, 5:00 pm PT
Pneumothorax is the most common serious complication of acupuncture. All practitioners should take advantage of simple, straightforward steps to reduce the risk to their patients. Actual cases will be presented and the medicolegal consequences discussed.
At the conclusion of this LIVE webcast physician participants will be able to:
Dr. Ochi is board-certified in both Otolaryngology and Medical Acupuncture and has been in practice for over 30 years in San Diego.
He graduated from Mayo Clinic College of Medicine, finished his Head & Neck Surgery residency at UC San Diego Health and completed a Pediatric Otolaryngology fellowship at Great Ormond Street Hospital for Children in London, England. He has received awards at the national, state and local levels for his clinical expertise and research.
The fee to participate in this LIVE activity is $40/members and $70/non-members.
Use the button below to register/pay for the live presentation.
Once paid, access instructions will be emailed to participant. At the conclusion of the LIVE activity, an evaluation/survey must be completed with attestation of credit/participation. Certificate of completion will be emailed when completed evaluation/survey is completed.
Accreditation/Designation
The American Academy of Medical Acupuncture is accredited by the Accreditation Council for Continuing Medical Education (ACCME). The AAMA designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statement
James W. Ochi, MD, DABMA has indicated no real or apparent conflicts.
The reviewers and activity planners have no financial relationships to disclose.
Disclosure Policy
AAMA must ensure that anyone who is in a position to control the content of the education activity has disclosed all financial relationships that you have had in the past 24 months (even if now ended) with ineligible companies. We define ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.